IACP has GREAT news - Blankenship and Appropriations!
Friday, December 18, 2015
Posted by: Dagmar Anderson
Great News from IACP!
Message from Dale Coker, IACP President
Last week, we sent you an email letting you know that David Miller, IACP’s EVP/CEO has decided to pursue a new opportunity. We cannot thank Dave enough for his years of service to IACP, especially during a time of extreme challenge and change in our profession. On behalf of the Board of Directors, we wish Dave well in his new position, and acknowledge the amazing impact he’s made for our members and our organization.
We’re extremely pleased to announce that Cynthia Blankenship, newly employed by the Rose Law Firm, has rejoined the IACP legislative team, and will help us continue the considerable momentum IACP has generated in Washington D.C.
As our Executive Search Committee, chaired by past president David Nicoletti, works to identify a new Executive Vice President, Cynthia will help us ensure that we don’t miss a beat on the many initiatives she’s begun over the last few years. She will continue her role as leader of the DQSA Coalition, which resulted from a strategic initiative from your Board of Directors. Cynthia was instrumental in the formation of this unprecedented alliance to ensure that our members’ interests and those of your patients continue to be heard on Capitol Hill. Along with IACP’s D.C. legislative consulting firm, Arnold & Porter, Cynthia will continue to work on moving forward Senate Bill 1406, ensuring that prescribers do not lose access to office use which is so critical to so many physician practices and the patients they serve.
And, we’re thrilled to announce that she will continue to shepherd the amazing work she has done on Appropriations language. Ready for some more good news? We’ve learned just this week that ALL of the Appropriations language IACP fought so hard for is included.
The Congressional Appropriations Committees rejected FDA's request for increased funding to implement the provisions related to compounding within the Drug Quality and Security Act. In addition, the Omnibus appropriations bill expresses grave concern from Congress that FDA has exceeded its authority under the DQSA by prohibiting all office-use compounding and restricting dispensing as well as distribution activities within the Memorandum of Understanding. In order to address these concerns, Congress has included language within the Omnibus appropriations legislation that mandates FDA to release guidance within 90 days of enactment that allows office-use compounding. The Omnibus also contains language that prevents FDA from restricting dispensing of compounded medications within the Memorandum of Understanding and mandates FDA to report to Congress within 90 days as to when the API positive list will be finalized.
This is a tremendous win, and we are extremely grateful to our champions in the United States House and Senate who continue to fight on behalf of compounding pharmacists to preserve patient access to vital compounded medications.
This win also is due to the dedication of the IACP Board of Directors, and our IACP Committees, including the Legislative Committee which has been deeply involved in the Appropriations effort. I could not be more proud of the IACP leadership team and their accomplishments over the last few years. We’ve gone through some really tough challenges as have you all, and I can say that we’re stronger than ever. We have an extremely capable leadership team ready to take us into 2016, our 25th anniversary year of serving compounding pharmacists!
Your continued membership and support of IACP is so critical to us. IACP is on a roll, and we want you there for the ride. Please make a donation to our One Fund campaign, today. Join your colleagues in supporting IACP and our continued work in DC to save your patients’ access to the compounded medications on which they depend!!
IACP President, RPh, FIACP